Cargando…

The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis

AIM: To evaluate the impact of PIK3CA mutation status on clinical outcomes of HR+ breast cancer treated with PI3K inhibitors. METHODS: A comprehensive literature search was conducted in online databases from inception to December 31, 2019. The main characteristics and prognostic data of each eligibl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Mingming, Li, Jin, Huang, Jiangsheng, Luo, Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238354/ https://www.ncbi.nlm.nih.gov/pubmed/32461963 http://dx.doi.org/10.1155/2020/1598037

Ejemplares similares

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
por: Payne, S N, et al.
Publicado: (2015)

PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials
por: Fillbrunn, Mirko, et al.
Publicado: (2022)

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
por: Vollbrecht, Claudia, et al.
Publicado: (2022)

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
por: Coussy, F., et al.
Publicado: (2020)

Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis
por: Wang, Shu, et al.
Publicado: (2020)

PIK3CA-mutations in breast cancer
por: Reinhardt, Kristin, et al.
Publicado: (2022)

PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition
por: McNeill, Robert S., et al.
Publicado: (2018)

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
por: Lehmann, Brian D, et al.
Publicado: (2014)

Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
por: Fiascarelli, Alessio, et al.
Publicado: (2023)

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer
por: Anderson, Elizabeth J., et al.
Publicado: (2020)

Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers
por: Fang, Wen-Liang, et al.
Publicado: (2015)

Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer
por: Malentacchi, Francesca, et al.
Publicado: (2019)

Inhibitors of STAT3, β‐catenin, and IGF‐1R sensitize mouse PIK3CA‐mutant breast cancer to PI3K inhibitors
por: Merino, Vanessa F., et al.
Publicado: (2017)

Initiating breast cancer by PIK3CA mutation
por: Miller, Todd W
Publicado: (2012)

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
por: Wang, Dong, et al.
Publicado: (2016)

Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors
por: Loconte, Daria C., et al.
Publicado: (2015)

Mutations of PIK3CA in gastric adenocarcinoma
por: Li, Vivian Sze Wing, et al.
Publicado: (2005)

Mutations in PIK3CA are infrequent in neuroblastoma
por: Dam, Vincent, et al.
Publicado: (2006)

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer
por: Jeong, Yeong Gyu, et al.
Publicado: (2023)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations
por: di Blasio, Laura, et al.
Publicado: (2018)

Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway
por: Yan, Wei, et al.
Publicado: (2021)

PIK3CA Gene Amplification and PI3K p110α Protein Expression in Breast Carcinoma
por: Firoozinia, Mohammad, et al.
Publicado: (2014)

Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
por: Chen, Li, et al.
Publicado: (2018)

Mutation of the PIK3CA oncogene in human cancers
por: Karakas, B, et al.
Publicado: (2006)

PIK3CA Mutations in Hepatocellular Carcinoma in Korea
por: Kim, Heesue, et al.
Publicado: (2013)

PIK3CA Mutational Analysis of Parathyroid Adenomas
por: Riccardi, Aaliyah, et al.
Publicado: (2020)

IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
por: Zorea, Jonatan, et al.
Publicado: (2018)

Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer
por: Avivar-Valderas, Alvaro, et al.
Publicado: (2018)

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer
por: Nixon, Mellissa J., et al.
Publicado: (2019)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
por: Hutchinson, Katherine E., et al.
Publicado: (2023)

Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
por: Diao, Fei-Yu
Publicado: (2021)

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
por: Turner, Stuart, et al.
Publicado: (2021)

Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases
por: Palimaru, Irina, et al.
Publicado: (2013)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

Detection of PIK3CA Mutations in Breast Cancer Bone Metastases
por: Daneshmand, Manijeh, et al.
Publicado: (2012)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer
por: Martínez-Sáez, Olga, et al.
Publicado: (2020)

PIK3CA mutations in breast cancer: A Tunisian series
por: Ben Rekaya, Mariem, et al.
Publicado: (2023)

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
por: Deshpande, Vikram, et al.
Publicado: (2011)

Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
por: Park, Ye‐Lim, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9ab0g4polnoqgmg4a8pca1b1e1